Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Common Equity (2016 - 2025)

Historic Common Equity for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to $2.7 billion.

  • Dexcom's Common Equity rose 3060.02% to $2.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.7 billion, marking a year-over-year increase of 3060.02%. This contributed to the annual value of $2.7 billion for FY2025, which is 3060.02% up from last year.
  • Dexcom's Common Equity amounted to $2.7 billion in Q4 2025, which was up 3060.02% from $2.7 billion recorded in Q3 2025.
  • Dexcom's 5-year Common Equity high stood at $2.7 billion for Q4 2025, and its period low was $1.6 billion during Q1 2021.
  • Moreover, its 5-year median value for Common Equity was $2.2 billion (2022), whereas its average is $2.2 billion.
  • Per our database at Business Quant, Dexcom's Common Equity surged by 7600.86% in 2021 and then plummeted by 1273.87% in 2024.
  • Dexcom's Common Equity (Quarter) stood at $2.0 billion in 2021, then increased by 4.39% to $2.1 billion in 2022, then dropped by 2.96% to $2.1 billion in 2023, then rose by 1.64% to $2.1 billion in 2024, then soared by 30.6% to $2.7 billion in 2025.
  • Its Common Equity stands at $2.7 billion for Q4 2025, versus $2.7 billion for Q3 2025 and $2.6 billion for Q2 2025.